Evidence map›Paper›PMID 38853876›Full record

ArticlebioRxiv : the preprint server for biology2024

Dynamic Single Cell Transcriptomics Defines Kidney FGF23/KL Bioactivity and Novel Segment-Specific Inflammatory Targets.

Rafiou Agoro, Jered Myslinski, Yamil G Marambio, Danielle Janosevic, Kayleigh N Jennings, Sheng Liu, Lainey M Hibbard, Fang Fang, Pu Ni, Megan L Noonan and 8 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Rafiou Agoro
Jered Myslinski
Yamil G Marambio
Danielle Janosevic
Kayleigh N Jennings
Sheng Liu
Lainey M Hibbard
Fang Fang
Pu Ni
Megan L Noonan
Emmanuel Solis
Xiaona Chu
Yue Wang
Pierre C Dagher
Takashi Hato
Kenneth E White

Funding

Changes in phosphate metabolism cause pathologic cardiac remodeling in chronic kidney disease (CKD)R01HL145528 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI FAUL, CHRISTIAN, WHITE, KENNETH E · 2019 to 2022
$2.4M
The role of antiviral programs in bacterial sepsisR01AI148282 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI HATO, TAKASHI · 2020 to 2024
$2.0M
Targeting sKlotho-FGF23 Interactions to Improve Pathological Phosphate Handling in CKDR01DK128252 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI WHITE, KENNETH E · 2021 to 2024
$1.8M
Modulating purine metabolism to treat kidney injury in sepsis.K08DK113223 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI HATO, TAKASHI · 2017 to 2021
$757k
Controlling renal oxidative stress in CKD via targeting FGF23 bioactivityR00DK129705 · NIDDK · JACKSON LABORATORY · PI AGORO, RAFIOU · 2023 to 2025
$737k
Novel Control of FGF23 in Metabolic Bone DiseaseR01DK112958 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI WHITE, KENNETH E · 2018 to 2020
$698k
Controlling renal oxidative stress in CKD via targeting FGF23 bioactivityK99DK129705 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI AGORO, RAFIOU · 2022 to 2023
$178k
Protective pathways in sepsis-induced renal injuryI01BX002901 · VA · RLR VA MEDICAL CENTER · PI Takashi Hato · 2016 to 2026
–
NIDDK NIH HHS K08 DK113223NIDDK NIH HHS K99 DK129705NIDDK NIH HHS R00 DK129705NIDDK NIH HHS R01 DK112958NIDDK NIH HHS R01 DK128252
6 · The paper itself

Abstract

FGF23 via its coreceptor αKlotho (KL) provides critical control of phosphate metabolism, which is altered in rare and very common syndromes, however the spatial-temporal mechanisms dictating renal FGF23 functions remain poorly understood. Thus, developing approaches to modify specific FGF23-dictated pathways has proven problematic. Herein, wild type mice were injected with rFGF23 for 1, 4 and 12h and renal FGF23 bioactivity was determined at single cell resolution. Computational analysis identified distinct epithelial, endothelial, stromal, and immune cell clusters, with differential expressional analysis uniquely tracking FGF23 bioactivity at each time point. FGF23 actions were sex independent but critically relied upon constitutive KL expression mapped within proximal tubule (S1-S3) and distal tubule (DCT/CNT) cell sub-populations. Temporal KL-dependent FGF23 responses drove unique and transient cellular identities, including genes in key MAPK- and vitamin D-metabolic pathways via early- (AP-1-related) and late-phase (EIF2 signaling) transcriptional regulons. Combining ATACseq/RNAseq data from a cell line stably expressing KL with the Translational statement: Inflammation and elevated FGF23 in chronic kidney disease (CKD) are both associated with poor patient outcomes and mortality. However, the links between these manifestations and the effects of inflammation on FGF23-mediated mineral metabolism within specific nephron segments remain unclear. Herein, we isolated an inflammatory pathway driven by TNF/NF-κB associated with regulating FGF23 bioactivity. The findings from this study could be important in designing future therapeutic approaches for chronic mineral diseases, including potential combination therapies or early intervention strategies. We also suggest that further studies could explore these pathways at the single cell level in CKD models, as well as test translation of our findings to interactions of chronic inflammation and elevated FGF23 in human CKD kidney datasets.

Identifiers

PMID38853876
PMCPMC11160572

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.